Navigation Links
HemoShear to Present Translational Findings from its Vascular and Liver Human Relevant Systems
Date:2/21/2013

CHARLOTTESVILLE, Va., Feb. 21, 2013 /PRNewswire/ -- HemoShear LLC, a biotechnology research company and leading developer of human and animal cell-based systems for discovery and assessment of new drug compounds, will present three separate studies from its predictive human relevant systems at The Annual Society of Toxicology (SOT) meeting, being held in San Antonio, Texas, on March 10-14, 2013.  SOT is the world's largest toxicology meeting and is attended by executives and scientists who are responsible for safety assessment of a wide range of drugs, chemicals and materials. 

(Logo: http://photos.prnewswire.com/prnh/20120416/PH86899LOGO)

Each presentation provides evidence of HemoShear's ability to create physiologically accurate vascular or liver conditions that differentiate drug candidates and predict human response at in vivo-level drug doses.

Presentation Information:

DATE: March 12, 2013
ABSTRACT #: 1459
TITLE: Controlled Hemodynamics and Transport in Primary Hepatocytes Shift Induction and Toxic Responses to Drugs Closer to in vivo Concentrations
AUTHORS: Dash A, Deering T, Thomas J, Blackman BR and Wamhoff BR. 

DATE: March 12, 2013
ABSTRACT #: 1216
TITLE: Preclinical Profiling and Computational Differentiation of Human Vascular Response to 95 drugs Using NextGen RNASeq Transcriptomics
AUTHORS: Figler RA, Lawson MJ, Mackey AJ, Berzin EL, Anstey JC, Schoppee-Bortz PD, Tilghman RW, Blackman BR and Wamhoff BR.

DATE:  March 14, 2013
Late Breaking Abstract
TITLE: Human Primary Hepatocytes Under Controlled Hemodynamics Elicit Induction Responses to Drugs at Clinical Cmax Concentrations
AUTHORS: Dash A, Deering T, Marukian S, Thomas J, Blackman BR and Wamhoff BR.  HemoShear collaborator KaLy-Cell, located in Plobsheim France, provided high quality human hepatocytes and biological sample analysis for this program.  KaLy-Cell co-authors include Desbans C, Alexandre E and Richert L.

Drs. Ajit Dash and Brian Wamhoff from HemoShear will attend the SOT meeting.  For more information on the content of HemoShear's abstracts, interested parties may visit the SOT website at http://www.toxicology.org/AI/PUB/Tox/2013Tox.pdf.

About HemoShear LLC
By applying physiologically accurate hemodynamics and biological transport to primary cell cultures, HemoShear creates human-relevant systems that accurately replicate the biology of organ systems and diseases for applications throughout drug discovery and development. Working in strategic partnerships with pharmaceutical, biotechnology and medical device companies, HemoShear generates meaningful data to increase confidence in decision-making, reduce risk of costly failures and identify efficacious therapies. HemoShear's science leads to new medicines and improves human health.  

 


'/>"/>
SOURCE HemoShear LLC
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. HemoShear Relocates and Expands Operations to Historic Martha Jefferson Property in Charlottesville, Virginia
2. HemoShear Adds Industry Veterans Mehmood Khan and Fred Brown to Board of Managers
3. HemoShear Unveils In Vitro Steatosis System at Annual Meeting of the Association for the Study of Liver Diseases
4. HemoShear Publishes Key Review on Human-Relevant Organotypic Systems
5. Masimo to Present at Raymond James 34th Annual Institutional Investors Conference
6. Express Scripts to Present at Upcoming Conferences
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. PAREXEL International To Present At Citi Global Healthcare Conference
9. Data Demonstrating the Safety and Efficacy of Chimerixs Antiviral CMX001 Presented at BMT Tandem Meetings
10. Oramed Pharmaceuticals to Present at the 4th Annual Drug Delivery & Formulation Summit in Berlin
11. Dr. Diana Bianchi Presents Data Demonstrating Verinata Healths Proprietary Technology Detects Genetic Abnormalities In Twin Pregnancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2017)... --  ZirMed Inc ., a recognized leader in cloud-based revenue ... been ranked #1 by its users for the seventh consecutive ... Survey. ZirMed was recognized as the top-ranked end-to-end revenue cycle ... over 200 beds and holds one of the longest #1 ... ...
(Date:9/18/2017)... , Sept. 18, 2017 ... fields of bioinformatics and immune engineering, today ... protective avian influenza A (H7N9) vaccine. ... related to seasonal influenza and presents a ... on prior exposure to be effective. Using ...
(Date:9/12/2017)... Sept. 12, 2017   EcoVadis , the leading platform for environmental, ... first annual edition of its Global CSR Risk and Performance Index. The ... EcoVadis, based on Scorecard Ratings that analyzed nearly 800,000 data points across ... ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the ... save lost souls in the Philippines. “The Journey: From the Mountains to the Mission ... of the Bible. She has taught all ages and currently teaches a class of ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... sleep apnea using cutting-edge Oventus O2Vent technology. As many as 18 ... characterized by frequent cessation in breathing. Oral appliances can offer significant relief to ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... the introduction of an innovative new design of the shoulder pad. The shoulder ... maximum comfort while controlling your pain while using cold therapy. By utilizing ice and ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s ... the 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. ... Center for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, ...
Breaking Medicine News(10 mins):